Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,916 Ovarian Cancer
clinical trials

Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Tacoma/Valley Radiation Oncology Centers-Jackson Hall
mi
from
Tacoma, WA
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
William Beaumont Hospital, Troy
mi
from
Troy, MI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Dayton Physicians LLC-Upper Valley
mi
from
Troy, OH
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Kaiser Permanente-Walnut Creek
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
MedStar Washington Hospital Center
mi
from
Washington DC,
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Aurora Cancer Care-Waukesha
mi
from
Waukesha, WI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Aspirus Regional Cancer Center
mi
from
Wausau, WI
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Mercy Medical Center-West Lakes
mi
from
West Des Moines, IA
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Kansas Hospital - Westwood Cancer Center
mi
from
Westwood, KS
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
SCL Health Lutheran Medical Center
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Dickstein Cancer Treatment Center
mi
from
White Plains, NY
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Presbyterian Intercommunity Hospital
mi
from
Whittier, CA
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Christiana Care Health System-Wilmington Hospital
mi
from
Wilmington, DE
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Southeastern Medical Oncology Center-Wilson
mi
from
Wilson, NC
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Inspira Medical Center Woodbury
mi
from
Woodbury, NJ
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Oncology Clinical Trial
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Cincinnati Cancer Institute
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Oncology Clinical Trial
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Status: Enrolling, Phase II
Updated: 12/31/1969
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Pacific Gynecology Specialists
mi
from
Seattle, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
AnMedical Health Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
MedStar Franklin Square Medical Center/Weinberg Cancer Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Billings Clinic Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Saint Francis Medical Center
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
TriHealth Cancer Institute-Westside
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Ellis Fischel Cancer Center
mi
from
Columbia, MO
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
The Mark H. Zangmeister Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Ephrata Community Hospital
mi
from
Ephrata, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Smilow Cancer Hospital Care Center-Fairfield
mi
from
Fairfield, CT
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Illinois CancerCare - Galesburg
mi
from
Galesburg, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Adams Cancer Center
mi
from
Gettysburg, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
NorthShore University HealthSystem-Glenbrook Hospital
mi
from
Glenview, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Saint Francis Cancer Center
mi
from
Greenville, SC
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Cherry Tree Cancer Center
mi
from
Hanover, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Queen's Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Methodist Hospital System
mi
from
Houston, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Kadlec Clinic Hematology and Oncology
mi
from
Kennewick, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Wellmont Holston Valley Hospital and Medical Center
mi
from
Kingsport, TN
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Sparrow Hospital
mi
from
Lansing, MI
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Women's Cancer Center of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Kaiser Permanente-Lone Tree
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Aurora Saint Lukes Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute - Nampa
mi
from
Nampa, ID
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Norris Cotton Cancer Center Nashua
mi
from
Nashua, NH
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
FirstHealth of the Carolinas-Moore Regional Hospital
mi
from
Pinehurst, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Sutter Roseville Medical Center
mi
from
Roseville, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Sutter Pacific Medical Foundation
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Memorial Health University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Stony Brook University Medical Center
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Palo Alto Medical Foundation-Sunnyvale
mi
from
Sunnyvale, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Kaiser Permanente-Vallejo
mi
from
Vallejo, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Legacy Salmon Creek Hospital
mi
from
Vancouver, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Northwestern Medicine Cancer Center Warrenville
mi
from
Warrenville, IL
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Sibley Memorial Hospital
mi
from
Washington DC,
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Aurora Cancer Care-Milwaukee West
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Oncology Clinical Trial
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Enrolling, Phase II, III
Updated: 12/31/1969
Aurora West Allis Medical Center
mi
from
West Allis, WI
Click here to add this to my saved trials
Endocrinology, Oncology, Reproductive Clinical Trial
Vigorous Exercise Versus Moderate Exercise to Improve Glucose Metabolism and Metabolic Parameters in Women With Polycystic Ovary Syndrome and Insulin Resistance: A Prospective Randomized Pilot Study
Status: Enrolling
Updated: 9/15/2015
UCSF Center for Reproductive Health
mi
from
San Francisco, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Status: Enrolling, Phase I, II
Updated: 12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Oncology Clinical Trial
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Keck Medical Center of USC Pasadena
mi
from
Pasadena, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Status: Enrolling, Phase I, II
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Oncology Clinical Trial
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling, Phase II
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling, Phase II
Updated: 12/31/1969
Cleveland Clinic Florida
mi
from
Weston, FL
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Southern California Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling, Phase II
Updated: 12/31/1969
Southeastern Regional Medical Center
mi
from
Newnan, GA
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling, Phase II
Updated: 12/31/1969
Cancer Treatment Centers of America Eastern Regional Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling, Phase II
Updated: 12/31/1969
Sarcoma Oncology Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling, Phase II
Updated: 12/31/1969
Florida Cancer Specialists-Sarasota
mi
from
Sarasota, FL
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Washington/Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Oncology Clinical Trial
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Enrolling, Phase II
Updated: 12/31/1969
Baylor Scott & White Health
mi
from
Temple, TX
Click here to add this to my saved trials
Solid Tumors Habouring NTRK Fusion Clinical Trial
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Solid Tumors Habouring NTRK Fusion Clinical Trial
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
Status: Enrolling, Phase II
Updated: 12/31/1969
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies
Status: Enrolling
Updated: 10/15/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Oncology Clinical Trial
Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Oncology Clinical Trial
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Status: Enrolling, Phase I
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Oncology Clinical Trial
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Status: Enrolling, Phase I
Updated: 12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Oncology Clinical Trial
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Status: Enrolling, Phase II
Updated: 12/31/1969
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
Oncology Clinical Trial
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Florida Cancer Specialists-Sarasota
mi
from
Sarasota, FL
Click here to add this to my saved trials
Oncology Clinical Trial
Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling, Phase I, II
Updated: 12/31/1969
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Oncology Clinical Trial
Safety Study of MGD009 in B7-H3-expressing Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
Carolina BioOncology Institute
mi
from
Huntersville, NC
Click here to add this to my saved trials
Oncology Clinical Trial
Safety Study of MGD009 in B7-H3-expressing Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
Oncology Clinical Trial
Safety Study of MGD009 in B7-H3-expressing Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
New York University
mi
from
New York, NY
Click here to add this to my saved trials
Oncology Clinical Trial
Safety Study of MGD009 in B7-H3-expressing Tumors
Status: Enrolling, Phase I
Updated: 12/31/1969
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab, Carboplatin, PLD, Pembrolizumab, or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Peggy and Charles Stephenson Oklahoma Cancer Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Oncology Clinical Trial
Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
Status: Enrolling, Phase I
Updated: 12/31/1969
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Endocrinology, Oncology, Reproductive Clinical Trial
Urinary DENND1A.V2 as a Predictor of Pubertal Hyperandrogenemia
Status: Enrolling
Updated: 1/18/2018
Center for Research in Reproduction
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Oncology Clinical Trial
A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer
Status: Enrolling, Phase
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Oncology Clinical Trial
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer
Status: Enrolling, Phase I, II
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
1 2 3 4 5 6 7 8 9 10 11 12 13 … 69